Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by DIANE C BODURKA and CHARLOTTE C SUN.
DIANE C BODURKA
Connection Strength
4.762
CHARLOTTE C SUN
  1. Caring for cancer patients in the future: a perfect storm on the horizon? Oncology (Williston Park). 2010 Dec; 24(14):1351-2.
    View in: PubMed
    Score: 0.378
  2. Quality of life for patients with epithelial ovarian cancer. Nat Clin Pract Oncol. 2007 Jan; 4(1):18-29.
    View in: PubMed
    Score: 0.288
  3. Sexual function after gynecologic cancer. Obstet Gynecol Clin North Am. 2006 Dec; 33(4):621-30, ix.
    View in: PubMed
    Score: 0.286
  4. Quality of life and gynecologic malignancies. Curr Oncol Rep. 2005 Nov; 7(6):459-65.
    View in: PubMed
    Score: 0.266
  5. Women's preferences for cancer risk management strategies in Lynch syndrome. Gynecol Oncol. 2019 03; 152(3):514-521.
    View in: PubMed
    Score: 0.167
  6. Gynecologic cancer survivor preferences for long-term surveillance. BMC Cancer. 2018 04 03; 18(1):375.
    View in: PubMed
    Score: 0.157
  7. Hormonal Maintenance Therapy for Women With Low-Grade Serous Cancer of the Ovary or Peritoneum. J Clin Oncol. 2017 Apr 01; 35(10):1103-1111.
    View in: PubMed
    Score: 0.145
  8. Room for improvement: An examination of advance care planning documentation among gynecologic oncology patients. Gynecol Oncol. 2016 09; 142(3):525-30.
    View in: PubMed
    Score: 0.139
  9. Dying well: How equal is end of life care among gynecologic oncology patients? Gynecol Oncol. 2016 Feb; 140(2):295-300.
    View in: PubMed
    Score: 0.134
  10. Survivors of gynecologic malignancies: impact of treatment on health and well-being. J Cancer Surviv. 2016 Apr; 10(2):261-70.
    View in: PubMed
    Score: 0.131
  11. Impact of Age and Primary Disease Site on Outcome in Women With Low-Grade Serous Carcinoma of the Ovary or Peritoneum: Results of a Large Single-Institution Registry of a Rare Tumor. J Clin Oncol. 2015 Aug 20; 33(24):2675-82.
    View in: PubMed
    Score: 0.130
  12. Perioperative blood transfusion in gynecologic oncology surgery: analysis of the National Surgical Quality Improvement Program Database. Gynecol Oncol. 2015 Jan; 136(1):65-70.
    View in: PubMed
    Score: 0.124
  13. Missed opportunities: Patterns of medical care and hospice utilization among ovarian cancer patients. Gynecol Oncol. 2014 Nov; 135(2):244-8.
    View in: PubMed
    Score: 0.122
  14. Patient preferences for side effects associated with cervical cancer treatment. Int J Gynecol Cancer. 2014 Jul; 24(6):1077-84.
    View in: PubMed
    Score: 0.121
  15. Lifestyle modification in cervical cancer survivors: an ongoing need. Int J Gynecol Cancer. 2014 Mar; 24(3):570-5.
    View in: PubMed
    Score: 0.118
  16. Risk perception, worry, and test acceptance in average-risk women who undergo ovarian cancer screening. Am J Obstet Gynecol. 2014 Mar; 210(3):257.e1-6.
    View in: PubMed
    Score: 0.116
  17. Reclassification of serous ovarian carcinoma by a 2-tier system: a Gynecologic Oncology Group Study. Cancer. 2012 Jun 15; 118(12):3087-94.
    View in: PubMed
    Score: 0.101
  18. Ethics consultation on a gynecologic oncology service: an opportunity for physician education. J Cancer Educ. 2011 Mar; 26(1):183-7.
    View in: PubMed
    Score: 0.096
  19. Clinicodemographic factors influencing outcomes in patients with low-grade serous ovarian carcinoma. Cancer. 2011 Aug 15; 117(16):3741-9.
    View in: PubMed
    Score: 0.096
  20. Satisfaction with ovarian carcinoma risk-reduction strategies among women at high risk for breast and ovarian carcinoma. Cancer. 2011 Jun 15; 117(12):2659-67.
    View in: PubMed
    Score: 0.095
  21. Survival after intestinal perforation: can it be predicted? Gynecol Oncol. 2009 Dec; 115(3):349-53.
    View in: PubMed
    Score: 0.087
  22. Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary. Obstet Gynecol. 2006 Aug; 108(2):361-8.
    View in: PubMed
    Score: 0.070
  23. Generalizability of cancer clinical trial results: prognostic differences between participants and nonparticipants. Cancer. 2006 Jun 01; 106(11):2452-8.
    View in: PubMed
    Score: 0.069
  24. Are women ready for the HPV vaccine? Gynecol Oncol. 2006 Oct; 103(1):151-4.
    View in: PubMed
    Score: 0.068
  25. Quality of life and sexual functioning in cervical cancer survivors. J Clin Oncol. 2005 Oct 20; 23(30):7428-36.
    View in: PubMed
    Score: 0.066
  26. Quality of life in cervix cancer survivors--what matters the most in the long-term? Gynecol Oncol. 2005 May; 97(2):307-9.
    View in: PubMed
    Score: 0.064
  27. Rankings and symptom assessments of side effects from chemotherapy: insights from experienced patients with ovarian cancer. Support Care Cancer. 2005 Apr; 13(4):219-27.
    View in: PubMed
    Score: 0.062
  28. Frozen section analyses as predictors of lymphatic spread in patients with early-stage uterine cancer. J Am Coll Surg. 2004 Sep; 199(3):388-93.
    View in: PubMed
    Score: 0.061
  29. Evaluation of patient chemotherapy education in a gynecology oncology center. Support Care Cancer. 2004 Aug; 12(8):577-83.
    View in: PubMed
    Score: 0.060
  30. Transfusion use and effect on progression-free, overall survival, and quality of life in upfront treatment of advanced epithelial ovarian cancer: evaluation of the European Organization for Research and Treatment EORTC-55971 Cohort. Int J Gynecol Cancer. 2023 01 03; 33(1):1-9.
    View in: PubMed
    Score: 0.055
  31. Patient preferences regarding side effects of chemotherapy for ovarian cancer: do they change over time? Gynecol Oncol. 2002 Oct; 87(1):118-28.
    View in: PubMed
    Score: 0.054
  32. Prospective phase II trial of levonorgestrel intrauterine device: nonsurgical approach for complex atypical hyperplasia and early-stage endometrial cancer. Am J Obstet Gynecol. 2021 02; 224(2):191.e1-191.e15.
    View in: PubMed
    Score: 0.046
  33. Pharmacoeconomic considerations in treating ovarian cancer. Pharmacoeconomics. 2000 Feb; 17(2):133-50.
    View in: PubMed
    Score: 0.045
  34. Prospective assessment of patient-reported outcomes in gynecologic cancer patients before and after pelvic exenteration. Gynecol Oncol. 2018 06; 149(3):484-490.
    View in: PubMed
    Score: 0.039
  35. Factors influencing fertility-sparing treatment for gynecologic malignancies: A survey of Society of Gynecologic Oncology members. Gynecol Oncol. 2017 12; 147(3):497-502.
    View in: PubMed
    Score: 0.038
  36. Treatment Patterns, Outcomes, and Costs for Bowel Obstruction in Ovarian Cancer. Int J Gynecol Cancer. 2017 09; 27(7):1350-1359.
    View in: PubMed
    Score: 0.038
  37. The Advance Care Planning Readiness Scale: Development and Validation of a Measure of Willingness to Discuss and Acceptance of End-of-Life Care in Gynecologic Cancer Patients. Int J Gynecol Cancer. 2017 05; 27(4):838-846.
    View in: PubMed
    Score: 0.037
  38. Nothing left to chance? The impact of locus of control on physical and mental quality of life in terminal cancer patients. Support Care Cancer. 2017 06; 25(6):1985-1991.
    View in: PubMed
    Score: 0.036
  39. The DISINFECT Initiative: Decreasing the Incidence of Surgical INFECTions in Gynecologic Oncology. Ann Surg Oncol. 2017 Feb; 24(2):362-368.
    View in: PubMed
    Score: 0.035
  40. Retrospective review of symptoms and palliative care interventions in women with advanced cervical cancer. Gynecol Oncol. 2015 Dec; 139(3):553-8.
    View in: PubMed
    Score: 0.033
  41. Feeling powerless: Locus of control as a potential target for supportive care interventions to increase quality of life and decrease anxiety in ovarian cancer patients. Gynecol Oncol. 2015 Aug; 138(2):388-93.
    View in: PubMed
    Score: 0.032
  42. Targeting those with decreased meaning and peace: a supportive care opportunity. Support Care Cancer. 2015 Jul; 23(7):2025-32.
    View in: PubMed
    Score: 0.031
  43. Prospective study of symptom assessment among patients with cervical cancer during concurrent chemoradiotherapy with weekly cisplatin or every-3-week cisplatin and 5-fluorouracil. Int J Gynecol Cancer. 2013 Oct; 23(8):1520-7.
    View in: PubMed
    Score: 0.029
  44. Validating the M. D. Anderson Symptom Inventory (MDASI) for use in patients with ovarian cancer. Gynecol Oncol. 2013 Aug; 130(2):323-8.
    View in: PubMed
    Score: 0.028
  45. Capturing the patient's experience: using qualitative methods to develop a measure of patient-reported symptom burden: an example from ovarian cancer. J Pain Symptom Manage. 2013 Dec; 46(6):837-45.
    View in: PubMed
    Score: 0.028
  46. Hormonal therapy for recurrent low-grade serous carcinoma of the ovary or peritoneum. Gynecol Oncol. 2012 Jun; 125(3):661-6.
    View in: PubMed
    Score: 0.026
  47. Unverifiable accomplishments and publications on applications for gynecologic oncology fellowships. Obstet Gynecol. 2012 Mar; 119(3):504-8.
    View in: PubMed
    Score: 0.026
  48. Low-grade serous primary peritoneal carcinoma. Gynecol Oncol. 2011 Jun 01; 121(3):482-6.
    View in: PubMed
    Score: 0.024
  49. Is low-grade serous ovarian cancer part of the tumor spectrum of hereditary breast and ovarian cancer? Gynecol Oncol. 2011 Feb; 120(2):229-32.
    View in: PubMed
    Score: 0.024
  50. Pelvic fractures after radiotherapy for cervical cancer: implications for survivors. Cancer. 2010 Feb 01; 116(3):625-30.
    View in: PubMed
    Score: 0.022
  51. Perception of screening and risk reduction surgeries in patients tested for a BRCA deleterious mutation. Cancer. 2009 Apr 15; 115(8):1598-604.
    View in: PubMed
    Score: 0.021
  52. Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant. Gynecol Oncol. 2009 Jul; 114(1):48-52.
    View in: PubMed
    Score: 0.021
  53. Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum. Gynecol Oncol. 2008 Mar; 108(3):510-4.
    View in: PubMed
    Score: 0.019
  54. Ethnic differences in socioeconomic status, diagnosis, treatment, and survival among older women with epithelial ovarian cancer. Int J Gynecol Cancer. 2008 Jul-Aug; 18(4):660-9.
    View in: PubMed
    Score: 0.019
  55. Comparison of the clinical behavior of newly diagnosed stages II-IV low-grade serous carcinoma of the ovary with that of serous ovarian tumors of low malignant potential that recur as low-grade serous carcinoma. Gynecol Oncol. 2007 Jun; 105(3):625-9.
    View in: PubMed
    Score: 0.018
  56. Prophylactic bilateral salpingo-oophorectomy compared with surveillance in women with BRCA mutations. Obstet Gynecol. 2006 Sep; 108(3 Pt 1):515-20.
    View in: PubMed
    Score: 0.018
  57. A phase II trial of oral capecitabine in patients with platinum--and taxane--refractory ovarian, fallopian tube, or peritoneal cancer. Gynecol Oncol. 2006 Sep; 102(3):468-74.
    View in: PubMed
    Score: 0.017
  58. Phase II trial of capecitabine in recurrent squamous cell carcinoma of the cervix. Gynecol Oncol. 2005 Jun; 97(3):840-4.
    View in: PubMed
    Score: 0.016
  59. Hormonal therapy for the management of grade 1 endometrial adenocarcinoma: a literature review. Gynecol Oncol. 2004 Oct; 95(1):133-8.
    View in: PubMed
    Score: 0.015
  60. Does tamoxifen use affect prognosis in breast cancer patients who develop endometrial cancer? Obstet Gynecol. 2004 Aug; 104(2):255-60.
    View in: PubMed
    Score: 0.015
  61. Vacuum-assisted closure in the treatment of gynecologic oncology wound failures. Gynecol Oncol. 2004 Feb; 92(2):586-91.
    View in: PubMed
    Score: 0.015
  62. Expression of c-ABL, c-KIT, and platelet-derived growth factor receptor-beta in ovarian serous carcinoma and normal ovarian surface epithelium. Cancer. 2003 Aug 15; 98(4):758-64.
    View in: PubMed
    Score: 0.014
  63. Cavitational ultrasonic surgical aspiration for the treatment of vaginal intraepithelial neoplasia. Gynecol Oncol. 2000 Aug; 78(2):235-41.
    View in: PubMed
    Score: 0.012
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.